Company news
Scancell Holdings PLC news in 2022
Scancell Holdings PLC's news releases, calls and decks from 2022, newest first.
Licenses Vaccitech technology to advance Modi-2
November 7, 2022
First patient dosed in expansion phase of ModiFY
October 31, 2022
Results for the year ended 30 April 2022
October 28, 2022
Directorate Changes
October 26, 2022
Signs Commercial License Agreement with Genmab
October 25, 2022
Change of Nominated Adviser
October 13, 2022
Preclinical data at the EuroMAbNet Annual Meeting
September 23, 2022
Change of Registered Office
September 6, 2022
First patient dosed in Cohort 2 of the ModiFY
August 16, 2022
Scancell to produce TCB antibodies
June 23, 2022
Phase 2 SCOPE trial of SCIB1 vaccine expanded
June 15, 2022
First patient dosed in Modi-1 Phase 1 trial
June 13, 2022
Change of Registered Holder of Shares
April 12, 2022
Modi-1 Phase 1/2 trial open for recruitment
April 11, 2022
Update on COVIDITY clinical trial
March 29, 2022
Scancell progresses its new anti-glycan mAb
March 17, 2022
Update on COVIDITY Phase 1 clinical trial
January 31, 2022
Interim Results for the 6 months ended 31 Oct 2021
January 26, 2022